Mutual Advisors LLC Has $2.02 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual Advisors LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% in the fourth quarter, HoldingsChannel reports. The firm owned 22,073 shares of the biopharmaceutical company’s stock after selling 1,005 shares during the quarter. Mutual Advisors LLC’s holdings in Gilead Sciences were worth $2,023,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC grew its position in Gilead Sciences by 149.1% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 5,205 shares in the last quarter. Albion Financial Group UT grew its position in shares of Gilead Sciences by 182.7% during the 4th quarter. Albion Financial Group UT now owns 783 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 506 shares during the period. Advisory Alpha LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $260,000. XML Financial LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $203,000. Finally, Genesis Private Wealth LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $362,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Oppenheimer raised their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Barclays raised their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Stock Up 0.2 %

Gilead Sciences stock opened at $93.07 on Friday. The firm has a market cap of $115.99 billion, a price-to-earnings ratio of 1,034.11, a PEG ratio of 1.31 and a beta of 0.18. The stock has a fifty day simple moving average of $91.65 and a two-hundred day simple moving average of $84.68. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.